Abstract
Data relevant to economic evaluation are being collected alongside clinical trials with increasing frequency. When these trials involve health outcomes and resource utilization in many different countries, numerous methodologic problems arise. This paper describes and discusses the methodology for economic evaluation that will be used in the Economic Substudy of GUSTO IIb, as an example of how to address the problems that arise in economic evaluations linked to international trials.
MeSH terms
-
Canada
-
Clinical Trials as Topic*
-
Cost-Benefit Analysis*
-
Europe
-
Fibrinolytic Agents / economics
-
Fibrinolytic Agents / therapeutic use
-
Health Resources / statistics & numerical data
-
Heparin / economics
-
Heparin / therapeutic use
-
Hirudin Therapy
-
Hirudins / analogs & derivatives
-
Hirudins / economics
-
Humans
-
International Cooperation
-
Multicenter Studies as Topic*
-
Myocardial Infarction / drug therapy
-
Myocardial Infarction / economics
-
Outcome Assessment, Health Care
-
Quality of Life
-
Quality-Adjusted Life Years
-
Recombinant Proteins / economics
-
Recombinant Proteins / therapeutic use
-
Research Design
-
United States
Substances
-
Fibrinolytic Agents
-
Hirudins
-
Recombinant Proteins
-
Heparin
-
desirudin